Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10118420 | 1.00 | PRCP (0.52) | PRCPF2KMT2AFKBP1ASMN1; SMN2 | |
| SCHEMBL22822702 | 0.88 | PRCP (0.54) | PRCPF2KMT2AFKBP1ASMN1; SMN2 | |
| SCHEMBL30309004 | 0.85 | F2 (0.52) | PRCPF2KMT2ASMN1; SMN2CYP3A4 | |
| SCHEMBL29521538 | 0.84 | F2 (0.51) | PRCPF2KMT2ASMN1; SMN2CYP3A4 | |
| SCHEMBL15802665 | 0.84 | PRCP (0.47) | PRCPF2KMT2AFKBP1ASMN1; SMN2 | |
| SCHEMBL15801179 | 0.83 | FKBP1A (0.46) | PRCPFKBP1A | |
| SCHEMBL5035720 | 0.83 | PRCP (0.48) | PRCPF2KMT2AFKBP1ASMN1; SMN2 | |
| SCHEMBL12972648 | 0.83 | FKBP1A (0.51) | PRCPF2KMT2AFKBP1ASMN1; SMN2 | |
| SCHEMBL10136487 | 0.83 | F2 (0.48) | F2KMT2ASMN1; SMN2TSHRL3MBTL1 | |
| SCHEMBL29368134 | 0.83 | F2 (0.51) | F2KMT2ACYP3A4MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9528111-B2 | Single-stranded nucleic acid molecule having amino acid backbone | BONAC CORPORATION (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20160108400-A1 | Single-Stranded Nucleic Acid Molecule for Controlling Gene Expression | BONAC CORPORATION (JP) | 2016-04-21 | — | — | US | disclosed |
| US-9206422-B2 | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton | BONAC CORPORATION (JP) | 2015-12-08 | — | — | US | disclosed |
| US-9200278-B2 | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton | BONAC CORPORATION (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20150011605-A1 | Single-Stranded Nucleic Acid Molecule for Controlling Gene Expression | BONAC CORPORATION (JP) | 2015-01-08 | — | — | US | disclosed |
| US-20140329886-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE HAVING AMINO ACID BACKBONE | BONAC CORPORATION (JP) | 2014-11-06 | — | — | US | disclosed |
| US-8785121-B2 | Single-stranded nucleic acid molecule for controlling gene expression | BONAC CORPORATION (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20140171486-A1 | Single-Stranded Nucleic Acid Molecule Having Nitrogen-Containing Alicyclic Skeleton | BONAC CORPORATION (JP) | 2014-06-19 | — | — | US | disclosed |
| US-20140171633-A1 | Single-Stranded Nucleic Acid Molecule Having Nitrogen-Containing Alicyclic Skeleton | BONAC CORPORATION (JP) | 2014-06-19 | — | — | US | disclosed |
| US-8691782-B2 | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton | BONAC CORPORATION (JP) | 2014-04-08 | — | — | US | disclosed |
| US-20120035246-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE HAVING NITROGEN-CONTAINING ALICYCLIC SKELETON | BONAC CORPORATION (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120010271-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE FOR CONTROLLING GENE EXPRESSION | BONAC CORPORATION (JP) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010271-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE FOR CONTROLLING GENE EXPRESSION | SRRT, SSU72, RPRD2 | PRCP 2054/4885F2 4862/4885KMT2A 1767/4885 |
| US-20140329886-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE HAVING AMINO ACID BACKBONE | ZFX, YBX1, SRRT | PRCP 1436/4885F2 4469/4885KMT2A 807/4885 |
| US-20140171633-A1 | Single-Stranded Nucleic Acid Molecule Having Nitrogen-Containing Alicyclic Skeleton | NSUN2, CTDSP1, RNGTT | PRCP 1887/4885F2 4836/4885KMT2A 1455/4885 |
| US-20120035246-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE HAVING NITROGEN-CONTAINING ALICYCLIC SKELETON | NSUN2, CTDSP1, RNGTT | PRCP 1887/4885F2 4836/4885KMT2A 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.